Download PDF
Horm Metab Res 2001; 33(2): 96-100
DOI: 10.1055/s-2001-12404
Original Clinical
© Georg Thieme Verlag Stuttgart · New York

Decrease of Hypothalamic Neuropeptide Y Gene Expression by Vanadyl Sulfate in Streptozotocin-Induced Diabetic Rats

I. M. Liu, T. C. Chi, J. T. Cheng
  • Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan City, Taiwan
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

In an attempt to elucidate the effect of vanadium compounds on the gene expression of neuropeptide Y (NPY), vanadyl sulfate (VOSO4) was orally administrated at the dose of 1 mg/kg body weight into streptozotocin-induced diabetic rats (STZ-diabetic rats) three times daily for 1 week. We found a marked lowering of plasma glucose with a significant decrease of food and water intake in these STZ-diabetic rats treated with VOSO4, although the weight gain was unaffected. The increase of hypothalamic NPY, both the mRNA level and peptide concentration, in STZ-diabetic rats was also reduced by this oral treatment of VOSO4. However, similar treatment of VOSO4 in normal rats failed to modify the feeding behavior and hypothalamic NPY gene expression. These data suggest that decrease of hypothalamic NPY gene expression by VOSO4 is related to the recovery of hyperphagia in diabetic rats lacking insulin.

Key words:

Vanadyl Sulfate - Neuropeptide Y Gene Expression - Diabetic Rat

References

  • 1 Chavez M, Seeley RJ, Havel P J, Friedman M I, Matson C A, Woods S C, Schwartz M W. Effect of a high-fat diet on food intake and hypothalamic neuropeptide gene expression in streptozotocin diabetes.  J Clin Invest. 1998;  102 340-346
    PubMedGoogle Scholar
  • 2 Marks J L, Waite K, Li M. Effects of streptozotocin-induced diabetes mellitus and insulin treatment on neuropeptide Y mRNA in the rat hypothalamus.  Diabetologia. 1993;  36 497-502
    PubMedGoogle Scholar
  • 3 Williams G, Gill J S, Lee Y C, Cardoso H M, Okpere B E, Bloom S R. Increased neuropeptide Y concentrations in specific hypothalamic regions of streptozotocin-induced diabetic rats.  Diabetes. 1989;  38 321-327
    PubMedGoogle Scholar
  • 4 Bai F L, Yamano M, Shiotani Y, Emson P C, Smith A D, Powell J F, Fohyama M. An arcuate-paraventricular and dorsomedial hypothalamic neuropeptide Y-containing system which lacks noradrenaline in the rat.  Brain Res. 1985;  33 172-175
    PubMedGoogle Scholar
  • 5 Frankish H M, McCarthy H D, Dryden S, Kilpatrick A, Williams G. Neuropeptide Y receptor numbers are reduced in the hypothalamus of streptozotocin-diabetic and food-deprived rats: further evidence of increased activity of hypothalamic NPY-containing pathways.  Peptides. 1993;  14 941-948
    CrossrefPubMedGoogle Scholar
  • 6 McKibbin P E, McCarthy H D, Shaw P, Williams G. Insulin deficiency is a specific stimulus to hypothalamic neuropeptide Y: a comparison of the effects of insulin replacement and food restriction in streptozotocin-diabetic rats.  Peptides. 1992;  13 721-727
    CrossrefPubMedGoogle Scholar
  • 7 Malabu U H, McCarthy H D, McKibbin P E, Williams G. Peripheral insulin administration attenuates the increase in neuropeptide Y concentrations in the hypothalamic arcuate nucleus of fasted rats.  Peptides. 1992;  13 1097-1102
    CrossrefPubMedGoogle Scholar
  • 8 Hirsova D, Koldovsky O. On the question of the absorption of insulin from the gastrointestinal tract during postnatal development.  Physiol Bohemoslov. 1969;  18 281-284
    PubMedGoogle Scholar
  • 9 Ramasarma T, Crane F L. Dose vanadium play a role in cellular regulation?.  Curr Topic Cell Regul. 1991;  20 247-301
    PubMedGoogle Scholar
  • 10 Cantley  L C Jr, Resh M D, Guidotti G. Vanadate inhibits the red cell (Na+, K+) ATPase from the cytoplasmic side.  Nature. 1978;  272 552-554
    PubMedGoogle Scholar
  • 11 Degani H, Gochin M, Karlish S J, Shechter Y. Electron paramagnetic resonance studies and insulin-like effects of vanadium in rat adipocytes.  Biochemistry. 1981;  20 5795-5799
    CrossrefPubMedGoogle Scholar
  • 12 Pederson R A, Ramanadham S, Buchan A M, McNeill J H. Long-term effects of vanadyl treatment of streptozotocin-induced diabetes in rats.  Diabetes. 1989;  38 1390-1395
    PubMedGoogle Scholar
  • 13 Malabu U H, Dryden S, McCarthy H D, Kilpatrick A, Williams G. Effects of chronic vanadate administration in the STZ-induced diabetic rats. The antihyperglycemic action of vanadate is attributable entirely to its suppression of feeding.  Diabetes. 1994;  43 9-15
    PubMedGoogle Scholar
  • 14 Hudson F TG. Toxicology and biological significance.  New York; Elsevier press 1964
    Google Scholar
  • 15 Domingo J L, Gomez M, Sanchez D J, Llobet J M, Keen C L. Toxicology of vanadium compounds in diabetic rats: the action of chelating agents on vanadium accumulation.  Mol Cell Biochem. 1995;  153 233-240
    CrossrefPubMedGoogle Scholar
  • 16 Shechter Y. Insulin-mimetic effects of vanadate. Possible implications for future treatment of diabetes.  Diabetes. 1990;  39 1-5
    PubMedGoogle Scholar
  • 17 Niu C S, Chang T W, Cheng J T. Changes of neuropeptide Y messenger RNA and peptide by drugs influencing endogenous norepinephrine content in cerebrocortex of the rat.  J Neurochem. 1996;  66 2100-2104
    PubMedGoogle Scholar
  • 18 Liu I M, Hsu F L, Chen C F, Cheng J T. Antihyperglycemic action of isoferulic acid in streptozotocin-induced diabetic rats.  Br J Pharmacol. 2000;  29 631-636
    PubMedGoogle Scholar
  • 19 Matsushita R, Sakurai H. Mechanism on insulin-like action of vanadyl sulfate: studies on interaction between rat adipocytes and vanadium compounds.  Biol Pharm Bull. 1995;  18 719-725
    PubMedGoogle Scholar
  • 20 Reuland D J, Cao Z X, Rosenhein L, Poehlein S, McCoy L, Turner J, Durham T, Ganguli S. The cellular uptake kinetics and acute biological effects of various oxovanadium species: a comparative study.  Horm Metab Res. 1998;  30 29-33
    PubMedGoogle Scholar
  • 21 Jallat-Marfaing P, Penicaud L. Effect of vanadium on regional brain glucose utilization in rats.  Physiol Behav. 1993;  54 407-409
    CrossrefPubMedGoogle Scholar
  • 22 Morely J E. Neuropeptide regulation of appetite and weight.  Endocr Rev. 1987;  8 256-287
    PubMedGoogle Scholar
  • 23 Nakai M, Watanabe H, Fujiwara C, Kakegawa H, Satoh T, Takada J, Sahu A. Leptin decreases food intake induced by melanin-concentrating hormone (MCH), galanin (GAL) and neuropeptide Y (NPY) in the rat.  Endocrinology. 1998;  139 4739-4742
    CrossrefPubMedGoogle Scholar
  • 24 Schwartz M W, Baskin D G, Bukowski T R, Kuijper J L, Fuster D, Lasser G, Prunkard D E, Porte D Jr, Woods S C, Seeley R J, Weigle D S. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice.  Diabetes. 1996;  45 531-535
    PubMedGoogle Scholar
  • 25 Havel P J, UriU-Hare J Y, Liu T, Stanhope K L, Stern J S, Keen C L, Ahren B. Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: reversal by insulin.  Am J Physiol. 1998;  274 R1482-R1491
    PubMedGoogle Scholar
  • 26 McKibbin P E, Cotton S J, McCarthy H D, Williams G. The effect of dexamethasone on neuropeptide Y concentrations in specific hypothalamic regions.  Life Sci. 1992;  51 1301-1307
    CrossrefPubMedGoogle Scholar
  • 27 Yuen V G, Orvig C, McNeill J H. Effects of bis(maltolato)oxovanadium(IV) are distinct from food restriction in STZ-diabetic rats.  Am J Physiol. 1997;  272 E30-E35
    PubMedGoogle Scholar

Prof. J. T.  Cheng

Department of Pharmacology,
College of Medicine, National Cheng Kung University

Tainan City, Taiwan
70101, R.O.C.


Phone: Phone:+ 886 (6) 237-2706

Fax: Fax:+ 886 (6) 238-6548

Email: E-mail:jtcheng@mail.ncku.edu.tw